IXT m200

Drug Profile

IXT m200

Alternative Names: Ch-mAb7F9; IXT-m200; METH-mAb

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Arkansas for Medical Sciences
  • Developer InterveXion Therapeutics
  • Class Drug withdrawal therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug abuse

Most Recent Events

  • 12 Oct 2017 Ch-mAb7F9 is still in phase I trial for Drug abuse (In volunteers) in USA
  • 10 Oct 2017 InterveXion Therapeutics plans the phase I/IIa STAMPOUT trial in Drug abuse in USA (NCT03336866)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Drug-abuse(In volunteers) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top